Partial androgen deficiency in aging type 2 diabetic men and its relationship to glycemic control

Corrales, J. J.; Burgo, R.M.; Garcı́a-Berrocal, B; Almeida, Maria das Graças; Alberca, I; González-Buitrago, José Manuel; Órfão, Alberto; Miralles, José Manuel Pavía

doi:10.1016/j.metabol.2003.12.016

Cited by 85 publications

(85 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The effects of testosterone administration on glycemic control of men with diabetes mellitus are much less certain. [63][64][65] It is premature to recommend testosterone treatment for the metabolic syndrome or diabetes mellitus in the absence of laboratory and other clinical evidence of hypogonadism. In men with hypogonadism and diabetes and or the metabolic syndrome, testosterone treatment for traditional hypogonadal symptoms may have other unproven benefits on their metabolic status (level 2a, grade B).…”

Section: Recommendation 5: Body Compositionmentioning

confidence: 99%

ISA, ISSAM, EAU, EAA and ASA recommendations: Investigation, treatment and monitoring of late-onset hypogonadism in males

et al. 2008

View full text Add to dashboard Cite

show abstract

Section: Recommendation 5: Body Compositionmentioning

confidence: 99%

ISA, ISSAM, EAU, EAA and ASA recommendations: Investigation, treatment and monitoring of late-onset hypogonadism in males

et al. 2008

View full text Add to dashboard Cite

show abstract

“…53 Diabetes is clearly related to hypogonadism, and studies have shown that 20-50% of men with type 2 diabetes mellitus have low serum total or free testosterone. [54][55][56][57] The low serum testosterone levels are associated with lower serum LH and FSH levels, suggesting that the lower serum testosterone levels is due to hypogonadotropic hypogonadism in type 2…”

Section: Obesity Metabolic Syndrome Type 2 Diabetes Mellitus and Lomentioning

confidence: 99%

“…Several studies have shown that testosterone replacement has a favorable impact on body mass, insulin secretion and sensitivity, lipid profile and blood pressure in hypogonadal men with the metabolic syndrome as well as type 2 diabetes mellitus. 47,56,105,106 There are many reasons why testosterone would reverse some of the factors contributing to visceral obesity, the metabolic syndrome and type 2 diabetes mellitus. Testosterone significantly inhibits lipoprotein lipase activity, which reduces triglycerides uptake into adipocytes in the abdominal adipose tissue.…”

Section: Androgen Treatment Of Hypogonadal Men With Obesity and Diabementioning

confidence: 99%

Obesity, low testosterone levels and erectile dysfunction

et al. 2008

View full text Add to dashboard Cite

Obesity is an important risk factor for many common diseases including cardiovascular disease (CVD), type 2 diabetes, cancer and erectile dysfunction (ED). Adipose tissues produce a number of adipokines and cytokines, which affect endothelial and metabolic function resulting in insulin resistance and the metabolic syndrome (risks factors for CVD). Both ED and metabolic syndrome improve with a reduction in body mass index (BMI). The relationships among obesity, metabolic syndrome, ED, sex hormonebinding globulin (SHBG) and serum total and free testosterone levels are complex and often confusing to the physician. It is known that BMI is inversely proportional to serum total testosterone concentrations; low serum SHBG levels in obesity contribute to the low serum total testosterone. Recent studies show that BMI is also inversely proportional to free testosterone concentration. The characteristic low serum testosterone concentrations observed in obese men are also present in men with the metabolic syndrome and type 2 diabetes mellitus. A small proportion of men with ED have hypogonadism; however, the proportion increases if these men are obese with manifestations of the metabolic syndrome or type 2 diabetes mellitus. ED is a common symptom in patients with type 2 diabetes who also have low testosterone levels. This review describes the relationships between low serum testosterone concentrations and ED in obese patients and those with metabolic syndrome and type 2 diabetes mellitus.

show abstract

“…Secondly, clinical and hormonal determinants of AS differed between the younger and older age groups of male patients with HF. To the best of our knowledge, this is the first study reporting the prevalence of AS in chronic cardiovascular disease, while AS and andropausal symptoms have been documented in men with other chronic diseases, such as type 2 diabetes, 26 osteoporosis, 27 and in men treated with hormonal ablation therapy for prostate cancer. 28 We have shown that AS (diagnosed based on the severity of andropausal symptoms using the Polish version of the AMS scale with the highest cut-off, that is, the total AMS score 50 points or more) 21,22 is common in men with HF aged from 40 to 59 years, affecting 28% of these patients, which is significantly higher than in the age-matched local healthy male population (7%).…”

mentioning

confidence: 90%